Table 1.
Characteristics of chronic hepatitis B patients with liver cirrhosis, hepatic fibrosis, and healthy controls.
| Variable | Chronic Hepatitis B | p-Value d | Healthy Controls (n = 100) |
p-Value e | ||
|---|---|---|---|---|---|---|
| No Fibrosis a (n = 167) |
Liver Fibrosis b (n = 347) |
Liver Cirrhosis c (n = 138) |
||||
| Age, years | 46 ± 1 | 50 ± 1 | 60 ± 0.9 | <0.0001 | 27.3 ± 0.9 | <0.0001 |
| Sex, % females | 49% | 33% | 28% | 0.00148 | 22% | 0.0031 |
| Ethnicity, % Caucasian | 100% | 100% | 100% | 1 | 100% | 1 |
| Alcohol consumption, % | 54% | 55% | 34% | 0.00015 | - | - |
| Previous treatment, % | 32% | 50% | 71% | <0.0001 | - | - |
| BMI, kg/m2 | 25.37 ± 0.39 | 25.67 ± 0.29 | 26.20 ± 0.41 | 0.1752 | - | - |
| Diabetes, % | 5% | 11% | 12% | 0.0175 | - | - |
| HT, % | 15% | 24% | 99% | <0.0001 | - | - |
| ALT, IU/L | 32.73 ± 1.64 | 37.43 ± 1.58 | 40.43 ± 2.71 | 0.0070 | - | - |
| AST, IU/L | 26.37 ± 1.17 | 29.68 ± 1.34 | 38.4 ± 2.2 | <0.0001 | - | - |
| ALB, IU/L | 41 ± 1.06 | 43.6 ± 0.25 | 40.8 ± 0.48 | 0.4838 | - | - |
| PLT, 109/L | 229 ± 4.58 | 208 ± 3.85 | 158 ± 6.06 | 0.0002 | - | - |
| HBV DNA, IU/mL | 8447 ± 3 828 | 15,015 ± 3 787 | 20,932 ± 269 | <0.0001 | - | - |
| HBeAg, % positive | 6% | 13% | 18% | 0.0014 | - | - |
| Anti-HBe, % positive | 92% | 82% | 66% | <0.0001 | - | - |
| Liver inflammation grade †,* | 1.5 (0–2) | 1.5 (1–3) | 1.5 (1.25–1.75) | 0.3017 | - | - |
| Liver fibrosis stage † | 0 (0–0) | 1 (0.5–3.5) | 4 (4–4) | <0.0001 | - | - |
Unless stated otherwise, data are shown as the mean ± standard error of the mean; † median value (interquartile range); * liver biopsy samples only (n = 132); a no scarring (stage 0); b fibrosis stages (I–III); c fibrosis stage IV; d liver cirrhosis vs. no fibrosis, e all CHB vs. healthy control group; p-values less than 0.05 are shown in bold. BMI, body mass index; HT, portal hypertension; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; PLT, platelet count; CHB, chronic hepatitis B.